The earnings call presented a mix of positive and negative aspects. While the company saw a notable increase in revenue and improvement in gross profit, challenges remain with the AlterG business underperforming and delays in Medicare payments impacting sales. The company's efforts to expand its U.S. pipeline and control operating expenses are encouraging, but the challenges with capital expenditures and payment processing times indicate areas that need attention.
Company Guidance
During Lifeward's Q3 2024 earnings call, the company provided detailed guidance on its financial and operational performance. They reported a 39% increase in revenue compared to the prior year quarter, with total earnings reaching $6.1 million. The ReWalk exoskeleton and other traditional products contributed $2.5 million, showing a 73% growth, while AlterG products accounted for $3.6 million. The company highlighted a 62% increase in U.S. leads due to expanded coverage and commercial efforts, resulting in a pipeline of approximately 70 qualified candidates for future claims. Lifeward's adjusted operating expenses were $6.7 million, marking the lowest in the previous five quarters, and they aim to reach breakeven with quarterly revenue of $12-13 million. The company anticipates a strong Q4 driven by ReWalk system expansion post-Medicare coverage and the introduction of the AlterG NEO model, expecting full-year revenue between $25-26 million.
Revenue Increase
Lifeward reported revenue of $6.1 million for Q3 2024, a 39% increase compared to $4.4 million in Q3 2023.
Successful ReWalk Placements
20 more individuals regained ambulation from ReWalk placements during the quarter.
Expansion of U.S. Leads
U.S. leads expanded by 62% over the prior year due to expanded coverage and commercialization efforts.
Improved Gross Profit
Gross profit increased to $2.2 million or 36.2% of revenue compared to $0.9 million or 19.6% in the prior year.
Lower Operating Expenses
GAAP operating expenses decreased to $5.4 million in Q3 2024 from $8.8 million in Q3 2023.
---
Rewalk Robotics (LFWD) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LFWD Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024
$2.37
$2.39
+0.84%
Aug 15, 2024
$3.12
$4.07
+30.45%
May 15, 2024
$5.19
$5.05
-2.70%
Feb 27, 2024
$6.49
$6.51
+0.31%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Rewalk Robotics (LFWD) report earnings?
Rewalk Robotics (LFWD) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Rewalk Robotics (LFWD) earnings time?
Rewalk Robotics (LFWD) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.